4//SEC Filing
PHARMACEUTICAL PRODUCT DEVELOPMENT INC 4
Accession 0001181156-11-000003
CIK 0001003124operating
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 9:12 AM ET
Size
27.3 KB
Accession
0001181156-11-000003
Insider Transaction Report
Form 4
HARTMAN JUDD
General Counsel
Transactions
- Disposition to Issuer
Stock Options (to buy)
2011-12-05−34,503→ 0 totalExercise: $20.45→ Common Stock (34,503 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−25,000→ 0 totalExercise: $26.64→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−36,227→ 0 totalExercise: $25.74→ Common Stock (36,227 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−18,632→ 0 totalExercise: $37.69→ Common Stock (18,632 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−41,403→ 0 totalExercise: $33.44→ Common Stock (41,403 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−46,630→ 0 totalExercise: $43.26→ Common Stock (46,630 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−45,000→ 0 totalExercise: $27.27→ Common Stock (45,000 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−15,526→ 0 totalExercise: $32.47→ Common Stock (15,526 underlying) - Disposition to Issuer
Restricted Stock Units
2011-12-05−15,000→ 0 total→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−6,211→ 0 totalExercise: $19.94→ Common Stock (6,211 underlying)
Footnotes (7)
- [F1]The stock options were cancelled pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Product Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger") in exchange for a cash payment equal to the difference (if any ) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.
- [F2]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/25/11, 2/25/12 and 2/25/13 but vesting was accelerated due to the Merger.
- [F3]The stock options were cancelled pursuant to the Agreement on the effective date of the Merger in exchange for a cash payment equal to the difference (if any ) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but vesting was accelerated due to the Merger.
- [F4]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 6/17/11, 6/17/12 and 6/17/13 but vesting was accelerated due to the Merger.
- [F5]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/18/10, 2/18/11 and 2/18/12 but vesting was accelerated due to the Merger.
- [F6]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.
- [F7]Each restricted stock unit (RSU) represents a contingent right to receive one share of PPDI common stock. The RSUs were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but became fully vested pursuant to the terms of the Agreement. The RSUs were disposed of pursuant to the terms of the Agreement in exchange for a cash payment of $33.25 per share upon the effective date of the Merger.
Documents
Issuer
PHARMACEUTICAL PRODUCT DEVELOPMENT INC
CIK 0001003124
Entity typeoperating
IncorporatedNC
Related Parties
1- filerCIK 0001003124
Filing Metadata
- Form type
- 4
- Filed
- Dec 5, 7:00 PM ET
- Accepted
- Dec 6, 9:12 AM ET
- Size
- 27.3 KB